Drug Profile
GSK 2983559
Alternative Names: GSK-559; GSK2983559Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories; Benzothiazoles; Quinazolines; Small molecules
- Mechanism of Action Receptor-interacting protein serine-threonine kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 30 Jul 2019 Discontinued - Phase-I for Inflammatory bowel diseases (In volunteers) in United Kingdom (PO) (GlaxoSmithKline pipeline July 2019)
- 19 Feb 2019 GlaxoSmithKline terminated a phase I trial for Inflammatory bowel disease (In volunteers) in United Kingdom due to non-clinical toxicology findings and reduced safety margins (PO) (NCT03358407)
- 11 Jan 2018 Phase-I clinical trials in Inflammatory bowel disease (In volunteers) in United Kingdom (PO) (NCT03358407)